Axitinib Tablets / 阿昔替尼片

Axitinib Tablets / 阿昔替尼片
Product Description

  • Largest-selling drug in the global renal cancer market – global sales reached 978 million USD in 2024, with a 5-year CAGR of 12.7%.

    • The only approved first-line targeted-immunotherapy combination in China (with toripalimab), listed as Category IA recommendation in 2024 CSCO guidelines.

    Excellent clinical efficacy – median PFS of 18 months and ORR of 58.1% when combined with toripalimab in first-line treatment.

    Shares sales channels with apalutamide in urology and oncology departments, enabling synergistic promotion.

    Read more Show less

    Biotech Pharmaceutical Co., Ltd.

    • Country/Region:
      China
    • Founded:
      2000
    • On CPHI since:
      2026
    • Certificates:
      1
    • Employees:
      1000 - 4999
    Company types
    Pharmaceutical company
    Primary activities
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile
    Categories
    more categories Show less
    Specifications
    • Details
      5mg
    • Selling Points
      Best selling product in renal cancer 
    • Supplied from
      China
    More specifications Fewer specifications

    Biotech Pharmaceutical Co., Ltd.

    • Country/Region:
      China
    • Founded:
      2000
    • On CPHI since:
      2026
    • Certificates:
      1
    • Employees:
      1000 - 4999
    Company types
    Pharmaceutical company
    Primary activities
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile

    More Products from Biotech Pharmaceutical Co., Ltd. (2)

    • Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

      Product Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

      • Large and fast-growing market – global sales reached 3.574 billion USD, with growth exceeding that of enzalutamide.

      Only the originator (Janssen) is available in China; generic entry is expected to achieve rapid volume uptake.

      Expanding patient pool – prostate cancer incidence is ...
    • Ebidetide Injection (JY09) / 益百得肽注射液

      Product Ebidetide Injection (JY09) / 益百得肽注射液

      1.Has a half-life of up to 240 hours and is the first bi-weekly GLP-1 receptor agonist globally to enter Phase III, significantly improving patient compliance.2.Precisely regulates insulin secretion only when blood glucose is elevated, resulting in an extremely low risk of hypoglycemia.3.Incidence of ...